Ahrens Investment Partners’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
$619K Sell
6,303
-11,318
-64% -$1.53M 0.31% 60
2022
Q4
$2.49M Sell
17,621
-14,557
-45% -$2.03M 1.13% 24
2022
Q3
$4.51M Buy
32,178
+9,483
+42% +$1.74M 2.38% 13
2022
Q2
$3.06M Buy
+22,695
New +$3.87M 1.35% 18

Other funds holding LABU

Ahrens Investment Partners's LABU Position: Q1 2023 in Review

Ahrens Investment Partners reduced its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 64% in Q1 2023, selling an estimated $1.53M and leaving 6,303 shares worth $619K. The position accounts for 0.31% of the portfolio, ranked #60.

Ahrens Investment Partners first reported a position in LABU in Q2 2022 and has held it in 4 quarters since. The position peaked at $4.51M in Q3 2022. 57 funds tracked by Wall St. Rank hold LABU as of Q1 2023.

  • Ahrens Investment Partners held 6,303 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $619K as of Q1 2023.
  • Ahrens Investment Partners sold 11,318 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2023, an estimated $1.53M.
  • Direxion Daily S&P Biotech Bull 3X ETF made up 0.31% of Ahrens Investment Partners's portfolio in Q1 2023, its #60 holding.
  • Ahrens Investment Partners first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2022 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $4.51M in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.